Recent news on Cravit

Astellas and Daiichi Sankyo figures fail to dazzle  -  May 16, 2007
Pharma Times (subscription),...in Japan and Europe, which rose 73.5% to 160.3 billion yen, while the antibiotic levofloxacin, sold in Japan as Cravit, was up 2.6% to 16.4 billion yen.

Fifty-Plus.Net International Inc. Announces Letter of Intent to ...  -  Apr 26, 2007
WM Experts (press release),Contacts: Fifty-Plus.net International Inc. David Cravit Senior Vice President (416) 363-7063 Website: www.50plus.com.

Daiichi Sankyo Announces Completion of Phase I Trial on the Anti ...  -  Apr 19, 2007
PharmaLive.com (press release),...on the Japanese market, including the antihypertensive Benicar (olmesartan medoxomil) and the synthetic antibacterial agent Cravit (levofloxacin).

Senior demographic faces fundamental change as baby boomers come ...  -  Feb 27, 2007
680 News,David Cravit, vice-president of marketing for the 50-Plus Group, says the one thing this report stresses is that there's no such thing as a "typical senior.

Older, wiser -- and safer  -  Mar 7, 2007
Toronto Sun,..."The older people get, they're more cautious, they're maybe physically not in the same kind of situations as younger people," said David Cravit,

Daiichi Pharmaceutical (Beijing) Granted Sales Promotion Permission  -  Feb 28, 2007
PharmaLive.com (press release),Daiichi Pharmaceutical (Beijing) plans to focus its sales promotions on the anti-infectives franchise that includes Cravit® and Tarivid®.

On the Spot: Colleen DeCourcy  -  Mar 12, 2007
Adweek,Copywriter at a retail ad agency in Toronto, Saffer Cravit & Freedman. A little bit on everything. I was two minutes out of school.

UPDATE 1-Daiichi Sankyo cuts 2009/10 operating profit goal  -  Feb 13, 2007
ReutersThis business year it has raised it earnings forecasts three times, bolstered by robust sales of Benicar, used to treat high-blood pressure, and Cravit,

DAIICHI SANKYO returns development rights of KAI-9803  -  Feb 9, 2007
PipelineReview.com (press release),...on the Japanese market, including the antihypertensive Benicar® (olmesartan medoxomil) and the synthetic antibacterial agent Cravit® (levofloxacin).

Patent Expiries of Leading Antibiotics From Several Pharmaceutical ...  -  Jan 9, 2007
PR Newswire (press release),The new Pharmacor report Emerging Antibacterial Agents finds that Johnson & Johnson's Levaquin, Sanofi-Aventis's Tavanic, Daiichi-Sankyo's Cravit,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional